Aardvark Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	62.44	47.05	61.64	9.74	15.56
Short-Term Investments	28.76	62.98	12.02	0.25	0.55
Cash & Short-Term Investments	91.2	110.03	73.66	9.99	16.11
Cash Growth	-39.71%	49.36%	637.44%	-37.98%	-
Other Current Assets	2.38	1.86	0.47	0.38	0.39
Total Current Assets	93.58	111.89	74.14	10.37	16.49
Net Property, Plant & Equipment	0.27	0.36	0.74	0.16	0.25
Other Long-Term Assets	4.74	4.94	2.64	0.01	0.01
Total Assets	98.59	117.18	77.51	10.54	16.76
Accounts Payable	4.49	2.07	2.3	1.04	0.26
Accrued Expenses	6.78	8.04	2.29	0.24	0.24
Current Portion of Leases	0.34	0.44	0.34	0.11	0.1
Total Current Liabilities	11.6	10.55	4.93	1.38	0.6
Long-Term Leases	-	-	0.44	0.05	0.16
Other Long-Term Liabilities	-	-	0.03	0	0.02
Total Long-Term Liabilities	-	-	0.47	0.05	0.18
Total Liabilities	11.6	10.55	5.39	1.43	0.78
Additional Paid-in Capital	224.48	222.47	3.68	2.94	2.61
Accumulated Other Comprehensive Income	0.01	0.08	-	-	-
Retained Earnings	-	-	-	-37.74	-30.53
Total Common Shareholders' Equity	224.49	222.55	3.68	-34.8	-27.92
Minority Interest	-	-	126.76	43.9	43.9
Shareholders' Equity	224.49	222.55	130.44	9.1	15.98
Total Liabilities & Equity	98.59	117.18	77.51	10.54	16.76
Total Debt	0.34	0.44	0.78	0.16	0.26
Net Cash (Debt)	90.86	109.59	72.88	9.83	15.84
Net Cash Growth	-17.08%	50.36%	641.67%	-37.97%	-
Net Cash Per Share	4.18	5.58	18.24	2.48	4.07
Book Value	224.49	222.55	3.68	-34.8	-27.92
Book Value Per Share	10.32	11.34	0.92	-8.79	-7.18
Tangible Book Value	224.49	222.55	3.68	-34.8	-27.92
Tangible Book Value Per Share	10.32	11.34	0.92	-8.79	-7.18

SEC Filings: 10-K · 10-Q